Two primary estimands were defined for analysis of the 36-week primary and secondary efficacy end points: a treatment-regimen estimand and an efficacy estimand ( Supplementary Appendix 3). Dulaglutide 4.5 mg was superior to 1.5 mg for weight loss at 36 weeks for both estimands (treatment regimen: −4.6 vs. ![]() Dulaglutide 3.0 mg was superior to 1.5 mg for reducing HbA 1c, using the efficacy estimand (ETD −0.17% P = 0.003) but not the treatment-regimen estimand (ETD −0.10% P = 0.096). At 36 weeks, dulaglutide 4.5 mg provided superior HbA 1c reductions compared with 1.5 mg (treatment-regimen estimand: −1.77 vs. ![]() Mean baseline HbA 1c and BMI in randomly assigned patients ( N = 1,842) was 8.6% (70 mmol/mol) and 34.2 kg/m 2, respectively.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |